Wolfe Research starts Amgen at Peer Perform given approaching patent cliffs
Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...
Amgen call volume above normal and directionally bullish
Bullish option flow detected in Amgen (AMGN) with 8,403 calls trading, 2x expected, and implied vol increasing over 3 points to 49.64%. Jan-25 ...
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.
Wall Street Indexes Dip With Focus on Trump Policies, Economic Data
The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...
STAT20h
Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
Amgen speaks out about bone density concerns with obesity drug
Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...
devdiscourse21h
Innovations and Challenges in Pharma: A Global Health Report
This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...